Novel drug delivery platform brings good news in Phase III trial

27 January 2017

Privately-owned Foresee Pharmaceuticals has announced top-line results from a Phase III study of its investigational prostate cancer drug FP-001 LMIS (leuprolide mesylate injectable suspension).

The primary efficacy end point of the trial was the suppression of serum testosterone according to certain parameters. This was reportedly achieved in 97% of the 137 subjects enrolled in the study.

The Taiwanese firm has a proprietary drug delivery platform it says will enable rapid development of new formulations of marketed drugs that offer significant product differentiation, targeting the same indications or new indications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK